Status:
UNKNOWN
Application of 68Ga-DOTA-TATE and 68Ga-DOTA-JR11 PET/CT in the Diagnosis and Evaluation of TIO
Lead Sponsor:
Peking Union Medical College Hospital
Conditions:
Tumor-Induced Osteomalacia
Eligibility:
All Genders
18-80 years
Phase:
PHASE1
Brief Summary
This is an open-label whole-body PET/CT study for investigating the value of 68Ga-DOTA-TATE and 68Ga-DOTA-JR11 PET/CT in patients with Tumor-induced osteomalacia.
Detailed Description
Tumor-induced osteomalacia (TIO), also known as oncogenic osteomalacia, is a rare paraneoplastic syndrome. The key to the cure of TIO is surgical resection of the culprit tumor. Over the last decade, ...
Eligibility Criteria
Inclusion
- suspected or confirmed untreated TIO patients;
- 68Ga-DOTA-TATE and 68Ga-DOTA-JR11 PET/CT within two weeks;
- signed written consent.
Exclusion
- pregnancy;
- breastfeeding;
- any medical condition that in the opinion of the investigator may significantly interfere with study compliance.
Key Trial Info
Start Date :
March 15 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 15 2022
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04689893
Start Date
March 15 2020
End Date
March 15 2022
Last Update
January 5 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking union medical college hospital
Beijing, Dongcheng, China, 100010